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Abstract
Heart failure continues to be a major public health problem with high morbidity and mortality
rates, despite the advances in medical treatment. Advanced heart failure patients have severe
persistent symptoms and a poor quality of life. Cardiac resynchronization therapy (CRT), an
invasive therapy which involves synchronized pacing of both right and left ventricles, improves
ventricular conduction delay and left ventricular performance. Several clinical trials of CRT
in medically refractory heart failure patients with wide QRS (> 120 ms), left ventricular
ejection fraction £ 35% and New York Heart Association (NYHA) class III and IV have shown
improved quality of life, NYHA class, left ventricular ejection fraction and reduced mortality.
About 30% of heart failure patients who receive CRT do not respond to treatment. Mechanical
dyssynchrony may play a role in identifying patients who may respond better to CRT treat-
ment. However, recent large scale clinical trials PROSPECT and RethinQ have challenged
this concept. The role of CRT in heart failure patients with narrow QRS (< 120 ms), NYHA
class I and II, atrioventricular nodal ablation in patients with atrial fibrillation and triple site
pacing are evolving. Our review discusses the current evidence, indications, upcoming trials
and future directions. (Cardiol J 2009; 16, 3: 197–209)
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Introduction
Despite advances in medical management,
heart failure continues to be a significant health
problem in the United States. With a high incidence
of 550,000/year and a prevalence of 5 million,
heart failure causes about 287,000 deaths in the US
each year [1, 2]. Hospitalizations due to heart
failure are increasing [1, 3, 4] and this is especially
true for the aging population [3, 5]. In 2006 the es-
timated direct cost for heart failure in the US was
$29.6 billion dollars [1, 2].
Mortality in patients with heart failure is mo-
stly due to progressive heart failure or sudden de-
ath related to arrhythmias [6, 7]. Even though
medications such as beta-blockers, angiotensin co-
nverting enzyme inhibitors and angiotensin receptor
blockers have been shown to decrease morbidity
and mortality [8–13], the prognosis in these patients
remains poor [14, 15]. A significant number of
heart failure patients have electromechanical dys-
synchrony which increases their mortality [16]. The
commonly described types of electromechanical
dyssynchrony are atrioventricular delay, intraven-
tricular delay, interventricular delay and intramural
delay [17].
Cardiac resynchronization therapy (CRT) is
a recent advance in managing heart failure patients with
New York Heart Association (NYHA) class III and IV
symptoms despite optimal medical management.
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Conceptual and mechanistic principles
Several studies have shown significant impro-
vements in cardiac function in heart failure patients
when treated with CRT [18–25]. CRT involves syn-
chronized stimulation of both right and left ventricles
so that they contract simultaneously, thereby
correcting interventricular conduction delay and im-
proving left ventricular (LV) contractility [14, 17].
Cardiac resynchronization therapy involves
placing an LV lead via the coronary sinus to achieve
LV pacing [14]. This is commonly done using
a transvenous approach, which involves initial
cannulation of the coronary sinus using a specially
designed sheath. Once cannulation of the coronary
sinus is achieved, retrograde venography is perfor-
med to identify the coronary sinus anatomy. A left
ventricular lead is then positioned in one of the side
branches such as marginal, posterior or posterola-
teral vein and adjusted to achieve adequate pacing,
stability and freedom from phrenic nerve or diaph-
ragmatic stimulation [14].
Cardiac resynchronization therapy decreases
the atrioventricular mechanical asynchrony by opti-
mizing the atrioventricular interval and thereby
decreases the late diastolic ventriculoatrial gradient
[17, 26]. Another significant benefit of pacing from
the LV lateral wall is early activation of LV papilla-
ry muscles which decreases the severity of mitral
regurgitation [27]. A combination of these functions
optimizes LV loading, improves myocardial contrac-
tility and even has a modest effect in improving dia-
stolic dysfunction [28].
Role of cardiac resynhronization therapy
in heart failure patients with wide QRS
Clinical studies with cardiac
resynchronization therapy
and implantable pacemaker
Early clinical studies have shown that biven-
tricular pacing in heart failure patients with wide
QRS (> 120 ms) improves LV hemodynamics [29–
–31], prompting subsequent randomized clinical
trials. In patients with wide QRS, CRT using bi-
ventricular pacing has been shown to facilitate re-
verse modeling of the left ventricle leading to in-
creased LV ejection fraction (LVEF), reduced mi-
tral regurgitation and reduced heart size [6].
The baseline characteristics and primary out-
comes of major trials comparing the role of CRT to
optimal medical management are shown in Tables 1
and 2 respectively. One of the earliest randomized
clinical trials was MUSTIC (Multisite Stimulation
Table 1. Characteristics of trials in heart failure patients with wide QRS.
Baseline CARE HF COMPANION   MIRACLE MUSTIC   MUSTIC AF
characteristics [24] [23]   [20, 32] [18] [19]
Medical CRT Medical CRT Medical CRT First Second UniRV– BiV–
Rx Rx Rx study study –BiV –UniRV
group  group
Randomization Yes Yes Yes Yes Yes
Follow up 24.9 months 12 months 6 months 6 months 6 months
Number 404 409 308 617 225 228 29 29 18 25
Mean QRS 160* 160* 158* 160* 165±20 167±21 172±22 175±19 209±18 209±21
Age 66* 67* 68* 67* 64±11 64±10.7 64±11 64±8 66±9 65±9
Men (%) 73 74 69 67 68 68 65.5 82.7 77 84
Ischemic (%) 40 36 59 54 58 50 37.3 37.3 143 13
NYHA III (%) 93 94 82 87 91 90 100 100 100 100
QoL NA NA 39 40 59±21 59±20 48±19 46±25 50±20 40±23
6 MWD NA NA 244* 274* 291±101 305±85 354±110 346±111 317±71 338±95
LVEF 25* 25* 22* 20* 21.6±6.2 21.8±6.3 23±7 23±7 30±12 23 ± 7
Diuretics (%) 44 43 94 94 93 94 94 94 100 100
ACEI or ARB (%) 95 95 89 89 90 93 96 96 100 100
Beta-blockers (%) 74 70 66 68 55 62 28 28 23 23
Spirinolactone (%) 59 54 53 53 NA NA 22 22 16 16
Digoxin (%) 45 40 NA NA 79 78 48 48 58 58
*Continuous measures reported as median values, NA — not available, CRT — cardiac resynchronization therapy, NYHA — New York Heart Associa-
tion, QoL — quality of life, LVEF — left ventricular ejection fraction, Rx — treatment, 6 MWD — six minute walk distance, ACEI — angiotensin-conver-
ting enzyme inhibitor, ARB — angiotensin II receptor blockers, BiV–UniRV — pacemaker was programmed biventricular (BiV) during first 3 months
then right ventricular (UniRV) during the second cross over period, first study group — pacemaker was programmed to be active first then inactive,
second study group — vice versa
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in Cardiomyopathies) [18, 19]. Cazeau et al. [18]
studied the role of CRT in 67 patients in sinus rhy-
thm with NYHA class III, LVEF £ 35%, and mean
QRS > 150 ms. This was a single-blind, randomi-
zed controlled cross-over study design. The study
involved a three month period of active atriobiven-
tricular pacing and a three month period of inactive
pacing (ventricular inhibited pacing at a basic rate
of 40 bpm). A significant improvement in quality
of life (QoL) score, and distance walked in six
minutes (6 MWD) were noted (Table 2).
Leclercq et al. [19] studied 59 patients with
NYHA class III with LV systolic dysfunction, and
wide QRS. These patients were in atrial fibrillation.
This was a single-blind, randomized cross-over
study design with two three month periods of right
univentricular vs. biventricular pacing. As compa-
red with univentricular pacing, effective biventri-
cular pacing improved peak oxygen uptake by 13%
and 6 MWD by 9.3% (Table 2).
Abraham et al. [20, 32] published the results
of the MIRACLE study (Multicenter InSync Ran-
domized Clinical Evaluation) which included 453 pa-
tients with moderate to severe heart failure symp-
toms (NYHA III–IV), LVEF £ 35% and QRS dura-
tion of £ 130 ms. Patients were randomized to
a CRT group or a control group for six months, while
continuing conventional medical therapy. Signifi-
cant improvement in 6 MWD, NYHA class, LVEF
and QoL scores were observed (Table 2). Moreover,
hospitalizations for worsening heart failure were re-
duced. Subsequent publications documented impro-
vements in echocardiographic volumes and ejection
fraction.
Clinical studies with cardiac
resynchronization therapy and
implantable cardioverter defibrillator
The CONTAK CD study [21] examined the sa-
fety and effectiveness of CRT when combined with
an implantable cardioverter defibrillator (ICD). Hig-
gins et al. [21] studied 490 patients with NYHA
II–IV, LVEF £ 35%, QRS ≥ 120 ms and with an exi-
sting indication for ICD. Patients were implanted
with a device capable of providing CRT and ICD
therapy and were then randomized to CRT or no
CRT. Patients were followed for up to six months.
The primary end point was progression of heart
failure, defined as all-cause mortality, hospitaliza-
tion for heart failure, and ventricular tachycardia/
/ventricular fibrillation requiring intervention.
A 15% (statistically non-significant) reduction in
heart failure progression was observed. However,
CRT improved peak oxygen consumption, 6 MWD
and LV dimensions and function.
The MIRACLE ICD trial [22] examined the
efficacy and safety of combined CRT and ICD the-
rapy in heart failure patients with NYHA class III
or IV despite optimal medical management and
who had LVEF £ 35% and QRS ≥ 130 ms. Three
hundred and sixty nine patients received a device
with combined capability of CRT and ICD and in
Table 2. Primary outcomes after cardiac resynchronization therapy at follow up in heart failure patients
with wide QRS (3 to 6 months).
CARE HF COMPANION MIRACLE MUSTIC MUSTIC AF
[24]  [23]  [20, 32]  [18]  [19]
Medical CRT Medical CRT Medical CRT First Second UniRV– BiV–
Rx Rx Rx study study –BiV –UniRV
group group
NYHA 2.7 ± 0.9 2.1 ± 1.0 38§ 61§ 32%¶ 52%¶ NA NA NA NA
QoL 40 ± 22 31 ± 22 –12 ± 23# –25 ± 26# –9* –18* 33.3 ± 25.7 ± 38.5 ± 34.1 ±
 22 24 21.4 20.6
Improvement NA NA 9 ± 84 33 ± 99 +10* +39* 384 ± 412.9 ± 341 ± 359 ±
6 MWD 78.9 116 100 121
All cause 120 82 77 131 16 12 0 1$ 0 1
mortality
Sudden death 38 29 18 48 7 5 0 1$ 0 1
Progressive HF 56 33 34 53 10 4 0 0 0 0
HF hospitali- 133 72 NA NA 34 18 9‡ 3$ 2 1
zations
#mean change, *median change, ¶percent improved by one or more class, §percent improved in NYHA class symptoms, $active pacing group, ‡inactive
pacing group, Rx — treatment, QoL — quality of life, 6 MWT — six minute walk distance, HF — heart failure, NA — not available, CRT — cardiac re-
synchronization therapy, BiV–UniRV — pacemaker was programmed biventricular (BiV) during first 3 months then right ventricular (UniRV) during the
second cross over period, first study group — pacemaker was programmed to be active first then inactive, second study group — vice versa
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the control group the CRT was off. At the six
month follow up, patients in the CRT group achie-
ved significant improvement in their QoL score,
peak oxygen consumption and functional capaci-
ty. However, there was no significant improve-
ment in 6 MWD, heart failure hospitalization and
LV size or function.
Major clinical trials with morbidity
and mortality as primary endpoints
Two major subsequent trials assessed morbi-
dity and mortality benefits, while the previously
mentioned studies looked at improvements in
symptoms and LV performance measures. The
COMPANION trial [23] (Comparison of Medical The-
rapy, Pacing and defibrillation in Heart Failure) ran-
domized 1,520 patients with NYHA class III or IV,
QRS ≥ 120 ms in a 1:2:2 ratio to receive optimal
medical therapy alone or in combination with either
CRT with a pacemaker or CRT with a pacemaker-
defibrillator. The primary composite end point was the
time to death from, or hospitalization for, any cause.
When compared to optimal medical therapy alone,
CRT with pacemaker decreased the risk of primary
end point by 19% (hazard ratio, 0.81; p = 0.014), and
CRT with a pacemaker-defibrillator decreased the risk
of primary end point by 20% (hazard ratio, 0.80;
p = 0.01). However there was only a nonsignificant
decrease in secondary end point of all cause mortali-
ty in the CRT pacemaker group while there was a si-
gnificant reduction in all cause mortality in the CRT
pacemaker-defibrillator group (Table 2, Fig. 1).
The CARE-HF study (Cardiac Resynchroniza-
tion in Heart Failure) [24] included 813 patients
with NYHA III or IV heart failure, LVEF £ 35%,
a LV end-diastolic dimension of at least 55 mm and
QRS duration of at least 120 ms on the electrocar-
diogram. The primary end point was time to death
from any cause, or unplanned hospitalization from
a major cardiovascular event. Significant differen-
ces were noted in the primary end point between
the CRT group vs. the medical therapy group (39%
vs. 55%) (Table 2, Fig. 2).
Cardiac resynchronization therapy
and mortality benefit
Four meta-analyses have studied the mortali-
ty benefits of CRT in heart failure patients. CRT in
heart failure patients with wide QRS has been
shown to decrease mortality from progressive
heart failure [33, 34] and also decrease all cause
mortality [34–36].
From the above clinical trials and meta-analy-
sis, it is clear that CRT reduces heart failure symp-
toms, and furthermore decreases mortality in me-
dically refractory heart failure patients with prolon-
ged QRS and low ejection fraction.
Current indications
For the ranking of level of evidence and classes of
recommendations by ACC/AHA/HRS guidelines [37]
writing committee, please see Appendices I and II.
The most recent ACC/AHA/HRS guidelines
[37] published in 2008 gives a class I indication for
treatment with CRT (with or without an ICD) in
patients who have LVEF £ 35%, a QRS duration
≥ 120 ms, and sinus rhythm, for the treatment of
NYHA functional class III or ambulatory class IV
heart failure symptoms with optimal recommended
medical therapy (Level of evidence A).
Class IIa recommendations include:
— (a) treatment with CRT with or without an ICD
is considered reasonable in patients who have
LVEF £ 35%, a QRS duration ≥ 120 ms, and
atrial fibrillation, for the treatment of NYHA
functional class III or ambulatory class IV
heart failure symptoms on optimal recommended
medical therapy (Level of evidence B);
— (b) treatment with CRT is considered reaso-
nable in patients with LVEF £ 35% with NYHA
functional class III or ambulatory class IV
symptoms who are receiving optimal recom-
mended medical therapy and who have
frequent dependence on ventricular pacing
(Level of evidence C).
Class IIb recommendations were given for tre-
atment with CRT in patients with LVEF £ 35% with
NYHA functional class I or II symptoms who are
receiving optimal recommended medical therapy
and who are undergoing implantation of a perma-
nent pacemaker and/or ICD with anticipated
frequent ventricular pacing (Level of evidence C).
Class III recommendations include:
— (a) treatment with CRT is not indicated for
asymptomatic patients with reduced LVEF in
the absence of other indications for pacing (Le-
vel of evidence B);
— (b) treatment with CRT is not indicated for pa-
tients whose functional status and life expec-
tancy are limited predominantly by chronic
non-cardiac conditions (Level of evidence C).
Non-response to cardiac resynchronization
therapy in wide QRS heart failure patients
Despite the established role of CRT in heart
failure patients with a wide QRS, there is a high
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rate of non-response to CRT in these patients [38].
Baseline QRS duration alone has been found to be
a poor predictor of clinical and echocardiographic
responses to CRT [39]. Clinically, it is often diffi-
cult to predict who will respond to CRT. Therefo-
re, there is a need to explore other possible factors
that might play a role to provide a higher response
rate to CRT. LV dyssynchrony is one such factor
recently shown to predict prognosis in patients with
CRT [40–42]. The incidence of LV dyssynchrony
in heart failure patients varies between 27% and
56% [43]. On the other hand, reported predictors
of non-response to CRT include ischemic heart di-
sease, severe mitral regurgitation, LV end-diasto-
lic diameter ≥ 75 mm, pre-implantation apical wall
motion abnormality and posterolateral ventricular
scar [44, 45].
Next, we describe the role of CRT in narrow
QRS heart failure patients, upcoming clinical trials
and future directions.
Figure 1. Kaplan-Meier estimates from COMPANION trial [23]. A. The differences in the primary end point —
12-month rates of death from or hospitalization for any cause (68% in the pharmacologic-therapy group vs. 56% in
the group that received a pacemaker as part of cardiac-resynchronization therapy, vs. 56% in the group that received
a pacemaker-defibrillator as part of cardiac-resynchronization therapy); B. The differences in secondary end point —
the 12-month rates of death from any cause (19% in the pharmacologic-therapy group, 15% in the pacemaker group,
and 12% in the pacemaker-defibrillator group); C. The differences in 12-month rates of death from or hospitalization
for cardiovascular causes (60% in the pharmacologic-therapy group vs. 45% in the pacemaker group vs. 44% in the
pacemaker-defibrillator group); D. The difference in the 12-month rates of death from or hospitalization for heart
failure (45% in the pharmacologic-therapy group vs. 31% in the pacemaker group vs. 29% in the pacemaker-
-defibrillator group). P values are for the comparison with optimal pharmacologic therapy. Reproduced with permis-
sion from the publishing division of Massachusetts Medical Society (MMS Reference Number: PS-2009-0630); PT —
pharmacologic therapy; P — pacemaker; PD — pacemaker defibrillator.
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Role of cardiac resynchronization therapy
in narrow QRS heart failure patients
In addition to the benefit of CRT in patients
with wide QRS, recent studies have looked at the
benefit of CRT in patients with narrow QRS dura-
tion (£ 120 ms) [46–53]. CRT has been shown to
improve hemodynamics in heart failure patients
with narrow QRS [53]. High prevalence of LV asyn-
chrony has been noted in heart failure patients de-
spite a narrow QRS complex [40].
The baseline characteristics and primary out-
comes of trials in narrow QRS complex heart failure
patients are shown in Tables 3 and 4 respectively.
Achilli et al. [46] studied the role of CRT in
52 patients with refractory heart failure. Patients
were eligible if there was echocardiographic evidence
of interventricular and intraventricular asynchrony
regardless of the QRS duration. The patient popu-
lation was divided into two groups: one with QRS
duration £ 120 ms and the other with > 120 ms.
Significant improvement in NYHA functional class,
LVEF, left ventricular end diastolic and systolic dia-
meter and mitral regurgitation area was observed in
a similar magnitude in both groups (Tables 3, 4).
Another study from the Netherlands by
Bleeker et al. [47] looked at 33 consecutive narrow
QRS complex (QRS duration £ 120 ms) heart failu-
re patients and compared the benefits of CRT to
33 consecutive heart failure patients having a wide
QRS > 120 ms. All patients had inclusion criteria
of LV dyssynchrony ≥ 65 ms on tissue doppler ima-
ging (TDI), NYHA class III or IV and LVEF £ 35%.
Significant improvement in clinical symptoms and
LV reverse modeling was observed in the narrow
QRS group and was comparable to the benefits in
wide QRS heart failure patients (Tables 3, 4).
Yu et al. [48] studied the role of CRT in 51 wide
QRS patients and 51 narrow QRS patients who had
NYHA class III or IV symptoms and baseline systo-
lic asynchrony. At three month follow up, there was
significant reduction of LV end-systolic volume in
both groups. Improvement in NYHA class, maximal
exercise capacity, 6 MWD and LVEF were obse-
rved in both groups (Tables 3, 4).
A larger study of 376 heart failure patients who
were not pre-selected by baseline mechanical dys-
synchrony was done by Gasparini et al. [49]. Simi-
lar benefits of improvement in 6 MWD, NYHA class,
LV end-systolic volume were seen in both narrow
QRS complex and wide QRS heart failure patients
with CRT. The long term death rate was lower in
the narrow QRS group compared to the wide QRS
group. This probably reflected the underlying pre-
existing mortality risks between the two groups. An
important finding of this study is that the improve-
ment in LV function persisted for a long duration
follow up (three years).
A systematic review of the role of CRT in nar-
row QRS (< 120 ms) heart failure patients by our
Figure 2. Kaplan-Meier Estimates from CARE-HF study [24]. A. The differences in the primary outcome — death from
any cause or an unplanned hospitalization for a major cardiovascular event; B. The differences in secondary outcome
— death from any cause. Reproduced with permission from the publishing division of Massachusetts Medical
Society (MMS Reference Number: PS-2009-0684); CR — cardiac resynchronization; MT — medical therapy.
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group done before the results of RethinQ were pu-
blished showed significant improvement in LVEF,
NYHA class and 6 MWD [54]. However, the stu-
dies in this meta-analysis were pre and post CRT
studies without a medically managed control gro-
up. Therefore the results need to be validated by
large scale clinical trials.
Recent clinical trials and ongoing studies
of cardiac resynchronization therapy in
narrow QRS heart failure patients
While all the studies mentioned above were
non-randomized studies without a placebo control-
led arm, ReThinQ [55] study (Cardiac Resynchro-
nization Therapy in Patients with Heart Failure and
Narrow QRS) was the first randomized controlled
study. Patients who had a standard indication for
ICD (ischemic or non-ischemic cardiomyopathy
with LVEF £ 35%), NYHA class III symptoms,
a QRS duration of £ 130 ms and who had evidence
of mechanical dyssynchrony measured on echocar-
diography, were included in the study. The prima-
ry end point was increase in peak oxygen consump-
tion during cardiopulmonary exercise testing at six
month follow up. The study showed that CRT in
heart failure patients with narrow QRS complex did
not improve peak oxygen consumption, Minnesota
Living With Heart Failure (MLWHF) score, 6 MWD
and LV volume or EF at six months.
Another protocol for a large scale multi-center
prospective randomized EchoCRT (Echocardiogra-
phy guided Cardiac Resynchronization Therapy)
[55] trial in heart failure patients with narrow QRS
complex patients was announced by the University
of Zurich in 2007 [56]. This trial is designed to eva-
luate the role of CRT in heart failure patients with
narrow QRS duration and who show mechanical
dyssynchrony as assessed by echocardiography.
More than 1,000 patients will be randomized to re-
ceive CRT or no CRT with ICD. The primary end
point is reduction of combined endpoint of all cause
mortality or hospitalization for cardiovascular events.
From Gasparini’s trial [49] we know that the
CRT benefits in heart failure patients with narrow
Table 3. Characteristics of trials in heart failure patients with narrow QRS.
Baseline Bleekar et al. [47] Yu et al. [48] Achilli et al. [46]          Gasparini et al. [49]
characteristics < 120 ms > 120 ms < 120 ms > 120 ms < 120 ms > 120 ms < 120 ms* > 120 ms
Randomization No (consecutive) No No No
Baseline LVD Yes Yes Yes No
+ normal QRS
Mortality data NA NA Yes Yes
Follow up 6 months 3 months 6 months 28 months
Number 33 33 51 51 14 38 45 331
Mean QRS 110 ± 8 175 ± 22 103 ± 13 163 ± 24 NA NA 109 ± 8 174 ± 26
Age 63 ± 11 67 ± 9 63 ± 11 66 ± 12 68.3 ± 8 70.1 ± 9 67.8 ± 9.1 66.3 ± 9.5
Male (%) 85 76 78.4 72.5 71 55 84.4 78.8
Female (%) 15 24 21.5 27.4 NA NA NA NA
Ischemic (%) 70 64 49 43.1  29 45 60 46
NYHA III 29 (88%) 29 (88%) 2.84 ± 0.46 3.24 ± 0.4 3.4 ± 0.5 3.6 ± 0.4 5 (11%)* 43 (13.8%)*
QoL 39 ± 18 42 ± 15 28 ± 14 37 ± 25 NA NA 36 ± 11 46 ± 14
6 MWD 274 ± 133 253 ± 124 333 ± 96 298 ± 99 276.4 ± 88.9 256 ± 65.4 308 ±114 316± 115
LVEF (%) 22 ± 6 21 ± 6 27.8 ± 7 25.2 ± 9.2 24.6 ± 5.0 22.6 ± 4.6 29.4± 4.3 28.9± 6.3
LVEDV1 (cc)/ 216 ± 781 238 ± 721 167 ± 471 194 ± 821 71.8 ± 77.4 ± NA NA
/LVEDD2 [mm] 9.222 10.622
LVESV1 (cc)/ 174 ± 751 189 ± 601 122 ± 421 148 ± 741 61.4 ± 64.8 ± 127.4 ± 29 144 ± 56
/LVESD2 [mm]  8.422 10.222
LVD 102 ± 32 113 ± 30 35.9 ± 14.0 38.3 ± 12.7 NA NA NA NA
Diuretics (%) 82 91 96 98 100 100 91.1 86.1
ACEI (%) 88 85 92 94 90 92 84.4 87.5
Beta-blockers (%) 76 79 67 71 60 64 84.4 78.8
QoL — quality of life, 6 MWD — six minute walk distance, LVD — left ventricular dyssynchrony, LVEF — left ventricular ejection fraction, LVEDV — left
ventricular end-diastolic volume, LVEDD — left ventricular end-diastolic diameter, LVESV — left ventricular end-systolic volume, LVESD — left ventricular
end-systolic diameter, HF — heart failure, NYHA — New York Heart Association, ACEI — angiotensin-converting enzyme inhibitor
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QRS duration may not become evident without
a longer duration of follow up. The results of Echo-
CRT trial [56] and perhaps results from ReThinQ
[55] after a longer duration of follow up (if conduc-
ted) would help us understand the role of CRT in
narrow QRS heart failure patients.
Lack of consensus regarding quantification
and role of mechanical dyssynchrony
Potential differences in the results between the
ReThinQ study and prior narrow QRS complex
studies could be the method of measurement of me-
chanical dyssynchrony. Beshai et al. [55] used the
opposite wall delay method to measure mechanical
dyssynchrony by using both TDI and M-mode echo-
cardiography. TDI was used to measure the mecha-
nical delay in the septal-to-lateral and anterosep-
tal-to-posterior walls and M-mode echocardiography
measured the mechanical delay in the septal-to-po-
sterior wall (obtained by M-mode in the parasternal
long-axis view) [55]. Yu et al. [48] used a dyssyn-
chrony index to measure mechanical dyssynchrony
by calculating the standard deviation of time to peak
velocity in ejection phase of 12 LV segments.
LV dyssynchrony was defined as the maximum
delay between peak systolic velocities among the
four walls within the left ventricle using TDI by
Bleeker et al. [47]. Evaluation of asynchrony by
Achilli et al. [46] involved both intraventricular and
interventricular asynchrony. Interventricular asyn-
chrony was defined as interventricular delay > 20 ms,
whereas intraventricular asynchrony was identified
when Q-LW > Q-E (Q-LW represents the poste-
rolateral LV wall activation delay and Q-E repre-
sents the QRS onset-beginning of transmitral filling
interval) and Q-LW > 9.9 corrected units (c.u. =
= measured interval in ms/÷ R-R interval) [46].
The Predictors Of Response to CRT (PRO-
SPECT) [57] study tested the performance of
12 echocardiographic parameters in 498 patients
with standard CRT indications. M-mode, pulsed
Doppler mode and TDI echocardiographic methods
were used. There was a high level of quality con-
trol, all 53 centers having undergone training on
image acquisition and assessment with oversight
and monitoring by a blinded core laboratory. The
sensitivity and specificity of 12 echocardiographic
parameters to predict clinical composite score
(combined score for improvement in all-cause mor-
tality, heart failure hospitalization, NYHA class, and
patient global assessment) varied widely, with
sensitivity ranging from 6% to 74% and specificity
ranging from 35% to 91%. The ability for predic-
ting LV end-systolic volume response also varied
widely, with sensitivity ranging from 9% to 77% and
Table 4. Primary outcomes after cardiac resynchronization therapy at follow up in heart failure patients
with narrow QRS.
Bleeker et al. [47] Yu et al. [48] Achilli et al. [46]       Gasparini et al. [49]
< 120 ms > 120 ms < 120 ms > 120 ms < 120 ms > 120 ms < 120 ms  > 120 ms
Reduction 0.9 ± 0.6 1.1 ± 0.6 0.73 ± 0.49 0.81 ± 0.68 1.6 ± 0.1 1.7 NA NA
in NYHA
Reduction 13 ± 16 17 ± 12 8 ± 19 18 ± 20 NA NA NA NA
in QoL
Improvement 89 ± 107 130 ± 95 46 ± 88 53 ± 61 93.5 ± 18.7 138.2 ± 27 182 128
6 MWD
Improvement 8 ± 8 9 ± 7 7.3 ± 6.3 8.3 ± 7.6 9 ± 0.9 10.6 ± 0.8 14 9
in LVEF (%)
Reduction 26 ± 321 35 ± 511 8.6 ± 141 16.1 ± 65.6 ± 71.6 ± NA NA
in LVEDV1 (cc)/ 17.61 8.522 10.722
/LVEDD2 [mm]
Reduction 39 ± 341 44 ± 461 17.1 ± 18.61 24.2 ± 55.6 ± 57.9 ± 71.8 55.3
in LVESV1 (cc)/ 211 8.222 1122
/LVESD2 [mm]
All cause mortality 9 14 NA NA 3 7 3 51
Sudden death 0 2 NA NA 1 4 1 5
Progressive HF 8 11 NA NA 2 2 0 35
*Differences between baseline and 12 months, QoL — quality of life, 6 MWT — six minute walk distance, LVEF — left ventricular ejection fraction,
LVEDV — left ventricular end-diastolic volume, LVEDD — left ventricular end-diastolic diameter, LVESV — left ventricular end-systolic volume,
LVESD — left ventricular end-systolic diameter, HF — heart failure
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specificity from 31% to 93%. The study could not
settle upon any single echocardiographic measure
of dyssynchrony which would predict a better re-
sponse to CRT. However, several small single cen-
ter studies using TDI have shown that mechanical
dyssynchrony may play a significant role in predic-
ting response to CRT [58–60].
The most significant challenge with regard to
measuring mechanical dyssynchrony is the lack of
consensus in favor of a single methodology. Apart
from the differences in the parameters used, the
differences in technical and interpretive challenges
make it even more difficult. Abraham et al. [60], in
their review, highlighted the importance of conti-
nuing to study the role of mechanical dyssynchro-
ny in patients undergoing CRT. Since there is
significant room for improvement in TDI and strain
imaging techniques, and therefore in the evaluation
of their role in predicting response to CRT, it may
be imprecise to conclude that CRT is not effective
in patients with narrow QRS heart failure and that
there is no significant role in echocardiographic
measurement of mechanical dyssynchrony [60]. As
outlined by Abraham et al. [60], perhaps a multifac-
tor dyssynchrony score which would factor in clini-
cal factors, QRS duration and multiple imaging pa-
rameters might predict response to CRT.
Upcoming clinical trials
and future directions
Role of cardiac resynchronization therapy
in NYHA class I or II heart failure patients
Most clinical trials [18–20, 23, 24], studied the
role of CRT in heart failure patients with NYHA
class III or IV. An observational registry analysis
from InSync/InSync ICD [61] compared the effects
of CRT in patients in NYHA class II with those in
class III or IV. CRT in heart failure patients with
NYHA class II showed similar improvements in LV
end-systolic and end-diastolic diameter, a similar
improvement in ejection fraction but no significant
improvement in NYHA class when compared to
heart failure patients with class III or IV.
Two large scale randomized clinical trials are
assessing the role of CRT in heart failure patients
with less severe NYHA classes. MADIT CRT [62]
is designed to evaluate whether cardiac resynchro-
nization therapy with defibrillator (CRT-D) will re-
duce the risk of mortality and heart failure events
in subjects with ischemic (NYHA class I–II) and
non-ischemic (NYHA class II) cardiomyopathy, LV
dysfunction (EF £ 30%), and prolonged intraven-
tricular conduction (QRS duration ≥ 130 ms). The
Resynchronization Reverses Remodeling in Systo-
lic LV Dysfunction (REVERSE) [63] study is an
ongoing randomized controlled trial assessing the
safety and efficacy of CRT in heart failure patients
in NYHA class II (82.3%) or asymptomatic (NYHA
class I) LV dysfunction with previous symptoms
(17.7%). The preliminary results from REVERSE
[63] presented at ACC 08 showed that CRT
in asymptomatic and mildly symptomatic heart
failure patients on optimal medical therapy reverses
LV remodeling. However, there was no statistically
significant difference in primary end point of all-
cause mortality [64].
Epicardial versus transvenous
left ventricular lead placement
CRT requires placement of right and LV leads
to have synchronous ventricular contraction which
augments LV output. The postero-lateral wall of the
left ventricle appears to be a preferred area of LV
lead placement [65, 66]. Currently, there are two
approaches to place the LV lead in the postero-
-lateral wall [66]. One is to place the LV lead by
catheter based access via coronary sinus and
coronary venous tree. The other approach is to do
open surgical access via a left lateral mini-thoraco-
tomy.
Catheter based transvenous implantation is the
much more commonly adopted method. However,
the success rate of LV lead placement through trans-
venous implantation depends upon operator skill and
experience, difficult coronary venous anatomy and
myocardial scar formation. These difficulties can
easily prolong the procedure time and fluoroscopy
time, and increase the required amount of potential-
ly nephrotoxic contrast dye. Open surgical epicar-
dial LV lead placement is an alternative method, and
one which is attractive especially following the de-
velopment of minimally invasive techniques [66, 67].
Doll et al. [66] randomized 80 consecutive pa-
tients with standard indications for CRT to receive
transvenous or epicardial LV lead placement. The
transvenous group had a shorter Intensive Care
Unit  stay, and shorter ventilation time but had pro-
longed exposure time to radiation and contrast
medium. At six months follow up no significant
differences in LV lead pacing, sensing and impedance
were noted. Similar benefits have been shown for
surgical epicardial placement method in other stu-
dies [68, 69]. With this limited data, the surgical
approach for LV lead placement appears to be an
alternative method in patients with difficult trans-
venous implantation conditions. More data is
needed to assess its long term safety and efficacy.
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Benefits of cardiac resynchronization
therapy in atrial fibrillation patients and
role of atrioventricular junction ablation
Most clinical studies have evaluated only the
short term benefits of CRT in heart failure patients
with atrial fibrillation (AF) [70–72]. The role
of CRT in heart failure patients with AF is still
evolving and the ACC/AHA/HRS guideline [37]
committee had given a class IIa recommendation
for treatment of heart failure patients in AF with
CRT. In the MUSTIC trial [71] the ejection fraction
improved by 4% in patients with AF compared to
a 5% increase in patients with sinus rhythm at
12 months follow up. Mitral regurgitation decreased
by 50% in patients with AF compared to 45% in
patients with sinus rhythm [71].
Molhoek et al. [72] studied the role of CRT in
30 patients who had a underlying rhythm of AF
with baseline NYHA class III or IV symptoms,
LVEF < 35% and QRS > 120 ms and a left bundle
branch block and compared them to 30 patients in
sinus rhythm with similar baseline parameters.
Significant improvement was observed in both
groups in NYHA class symptoms, Minnesota QoL
score and 6 MWD. However the number of non-
-responders was higher in the patients with AF.
Another recent study showed a similar observa-
tion that new onset AF was associated with
failure to CRT [73].
In patients with permanent AF, adequate rate
control to relieve symptoms with pharmacological
therapy alone is sometimes difficult. These patients
can develop rapidly conducted AF despite maximally
tolerated pharmacological treatment, and eventually
develop heart failure. In these situations atrioven-
tricular junction ablation is performed and pacing
is done to achieve relief of symptoms and increase
exercise tolerance. Gasparini et al. [74] studied the
long-term effects of atrioventricular junction abla-
tion on ventricular function, reverse modeling and
exercise tolerance in patients with AF and compared
to patients in whom adequate heart rate was achie-
ved with pharmacological agents. The study showed
that sustained long term improvement of LV func-
tion and functional capacity was achieved in CRT
patients with AF only if atrioventricular junction
ablation was performed.
However, it should be noted that the patient
population who underwent atrioventricular junction
ablation in this study were much younger and the
reason for atrioventricular junction ablation was not
drug refractory control of ventricular rate during AF,
but for suboptimal biventricular pacing. Also the mean
ventricular rate was 80 beats/min, which is much
lower than the usual population referred for atrioven-
tricular junction ablation. Nevertheless, this is an
important concept which deserves further study.
Three site pacing vs. dual site pacing
Apart from the conventional LV lateral wall pa-
cing site, placing leads in additional pacing sites has
generated significant interest recently. It is
conceivable that additional pacing in different ventri-
cular sites might lead to multiple waves of electrical
activation and thereby reduce dyssynchrony [75].
Triple Resynchronization In Paced Heart Failu-
re Patients (TRIP-HF) by Leclercq et al. [76] is the
first study to compare triple site stimulation (two
epicardial transvenous leads placed on the anterior
and lateral or posterolateral LV wall and one RV lead)
with conventional biventricular pacing. It showed
that triple site stimulation pacing achieved more LV
reverse modeling compared to conventional biven-
tricular pacing. Triple site pacing patients achieved
a higher ejection fraction and smaller LV end-systo-
lic volume compared to biventricular pacing.
As noted in the editorial by Auricchio et al. [75],
TRIP-HF was performed in patients with a slow
ventricular rate during AF in need of antibradycar-
dia pacing. The benefits of triple site pacing need
to be studied in a more common group of heart
failure patients with sinus rhythm and ventricular
conduction disturbances [75].
Conclusions
Cardiac resynchronization therapy has been
shown to have significant benefit in terms of symp-
tomatic relief and LV reverse remodeling and mor-
tality in heart failure patients with wide QRS com-
plex. Non-response to CRT in these patients
remains an important concern. Other unresolved
issues include the role of CRT in heart failure
patients with narrow QRS complex, AF and atrio-
ventricular nodal ablation, NYHA class I and II, the
method of LV lead placement, and triple site
pacing.
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